The Members of the Board of Trustees are thoughtful, engaged, and committed to the work of BioNJ and we are deeply indebted for their passion for Patients and for inspiring our work each day.
Chairman: Christopher J. Schaber, Ph.D.
President and CEO, Soligenix, Inc.
Dr. Schaber has over 29 years of experience in the pharmaceutical and biotechnology industry. He has been the President and CEO and a Director of Soligenix since August 2006. Dr. Schaber was appointed Chairman of the Board on October 8, 2009. He has serves on the Board of Directors for the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organization for Rare Diseases (“NORD”) and the American Society for Blood and Marrow Transplantation (“ASBMT”) since October 2009 and July 2009, respectively.
Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories.
Dr. Schaber received his BA degree from Western Maryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his Ph.D. degree in Pharmaceutical Sciences from the Union Graduate School.
Immediate Past Chair: James Sapirstein, R.Ph., MBA
President and CEO, AzurRx BioPharma
Mr. Sapirstein has served over 35 years in the pharmaceutical industry. He is currently the President and CEO of AzurRx BioPharma. He has been part of almost two dozen drug product launches and specifically either led or has been a key member of several HIV product launches into different new classes of therapeutics at the time.
Mr. Sapirstein began his career in 1984 with Eli Lilly in sales, moving to Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its commercial teams in the U.S. and abroad, rising to become a Product Director. He joined Bristol-Myers Squibb as the Director of International Marketing in the Infectious Diseases group in 1996. While at BMS, he worked on several important HIV/AIDS projects, including Secure the Future.
Mr. Sapirstein started his career in smaller biotech companies when he later joined Gilead Sciences, Inc. (GILD) in order to lead the Global Marketing team in its launch of Viread (tenofovir). In 2002, he accepted the position of Executive Vice President, Metabolic and Endocrinology, for Serono Laboratories. Later, in 2006, he became the founding CEO of Tobira Therapeutics, then a private company. Tobira Therapeutics was acquired by Allergan in 2016. In 2012, Mr. Sapirstein became the CEO of Alliqua Biomedical at Alliqua, Inc. Thereafter, he served as CEO of ContraVir Pharmaceuticals from March 2014 until October 2018. All of these are publicly listed companies. Mr. Sapirstein has raised over $200M in venture capital and public capital markets financing in his various engagements as CEO. He was named as a Finalist for Ernst & Young Entrepreneur of the Year award in 2015 as well as in 2016.
He holds board positions on Marizyme (MRZM) (Executive Chairman), Enochian Biosciences (ENOB) and Leading Biosciences. In addition, Mr. Sapirstein is a Board Director for BIO, the leading biopharma industries organization promoting public policy and networking in the health care space, where he sits on both the Health Section and Emerging Companies Section Governing Boards.
Mr. Sapirstein received an MBA from Fairleigh Dickinson University in 1997, and a BS (Pharmacy) from Rutgers University in 1984.
President and CEO: Debbie Hart, MS, CAE, APR
President and CEO, BioNJ
Ms. Hart, founding President and CEO of BioNJ, is dedicated to the mission and work of BioNJ. She worked alongside New Jersey’s biotechnology industry leaders to establish BioNJ in 1994 and has been dedicated to the organization since then. Ms. Hart has been active on the boards and committees of numerous government and academic institutions.
Ms. Hart was recently named by Governor Murphy to the New Jersey Commission on Science, Innovation and Technology; as co-chair of the New Jersey Higher Education Strategic Plan Research, Innovation and Talent Working Group; and the New Jersey Commission on Higher Education and Business Partnership. She served as chair of the bipartisan, bicameral New Jersey Biotechnology Task Force which was charged with making recommendations to the Legislature for fostering the growth of the biotechnology industry in New Jersey. The report was issued in June 2018. Ms. Hart is a founding board member and officer of OpportunityNJ, a non-profit organization working toward a strong and sustainable State economy; and serves on the boards of the New Jersey Chamber of Commerce and Choose New Jersey.
Ms. Hart serves on the New Jersey Presidents Council’s branding and marketing task force for New Jersey institutions. She was appointed to the New Jersey Commission on Higher Education and Business Partnerships and to the NJ Council on Innovation. She was named to the Advisory Boards of the New Jersey Innovation Institute and the Institute for Life Sciences Entrepreneurship at Kean University. She served as a member of the New Jersey Economic Development Authority’s (EDA) Technology Advisory Board and is a former member and Chair of EDA’s Commercialization Center for Innovative Technologies (CCIT). Additionally, Ms. Hart served on the transition teams of two former New Jersey governors and was appointed by two Governors to the New Jersey Israel Commission for her work in economic development.
Past government support activities include the Prosperity New Jersey Pharmaceutical and Biotechnology Cluster Study commissioned by a former Governor and conducted by Professor Michael Porter of the Harvard Business School, the Jobs Growth and Economic Development Commission established by a former Governor and chaired by Dr. Roy Vagelos as well as the Task Force on Higher Education Quality and Competitiveness of the State. Ms. Hart also served on the Business Task Force established by the New Jersey State Legislature in 2011.
A strong advocate for advancing education, Ms. Hart serves as a board member of the Rutgers University Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management at Rutgers University Business School, and has served on the Advisory Board of the College of Science and Mathematics at Montclair University, the Rothman Institute of Entrepreneurship at Fairleigh Dickinson University’s Silberman College of Business and the Science Advisory Board at Rider University as well as the advisory boards for the New Jersey Institute of Technology’s (NJIT) Biomedical Engineering Program, Monmouth University’s School of Science, Technology and Engineering and as a Director of the Liberty Science Center’s Women’s Leadership Council.
Ms. Hart served on the advisory board that guided the establishment of the nationally recognized Monmouth County Biotechnology High School and as a member of the New Jersey Healthcare Businesswomen’s Association (HBA) Advisory Board. In 2005, she delivered the Commencement Address at Raritan Valley Community College’s graduation ceremonies.
As an advocate for the industry, Ms. Hart has testified before State and federal legislative committees. She is also a frequent speaker at industry events, including serving as the Keynote speaker at the Russian Pharmaceutical Forum in St. Petersburg, Russia; the Knowledge for Growth Conference in Ghent, Belgium; the Women’s Clinical Leadership Forum at the Partnerships in Clinical Trials conference in Orlando, Florida; and the Shanghai Bio Conference in Shanghai.
Ms. Hart was honored by the Women’s Fund of New Jersey as a Woman Advancing Science, and she and BioNJ were recognized by NJIT with a New Jersey Inventors Hall of Fame Award.
Ms. Hart is an NJBIZ New Jersey’s Best 50 Women in Business honoree. In March 2014 in commemoration of Women’s History Month, she was nominated by Assemblywoman Pamela Lampitt and honored by the New Jersey General Assembly as a Woman Advancing Science. In May 2014, Debbie was named to PolitickerNJ’s Health Care Power List of 2014. In 2015, she was named as one of HudsonMod Magazine’s list of Women in Power and one of New Jersey’s Top 25 Leading Women Entrepreneurs & Business Owners by Leading Women Entrepreneurs.
More recently, Ms. Hart was named one of the world’s 100 Most Influential People in Biotechnology by Scientific American Worldview; to ROI-NJ’s 2019 Influencers Power List; to the 2020 NJBIZ Health Care Power 50 for the second year in a row, to the 2019 NJBIZ Manufacturing 50, to PharmaVOICE‘s 2019 100 Most Inspiring People list; one of New Jersey’s top CEOs by COMMERCE Magazine and for the eighth time in 2020 to the NJBIZ Power 100, a listing of the 100 most influential people in New Jersey business.
Ms. Hart holds an M.S. from the S. I. Newhouse School at Syracuse University where she graduated cum laude and a B.A. from Trenton State College, now The College of New Jersey, where she graduated magna cum laude.
Vice Chairman: Daniel J. O’Connor, J.D.
President and CEO, OncoSec Medical, Incorporated
Mr. O’Connor, a life-long resident of New Jersey, is the CEO, President and Director of OncoSec Medical Incorporated, a New-Jersey based biotech company developing TAVO, an intratumoral cancer immunotherapies using IL-12. During his two years as CEO, Mr. O’Connor has launched two KEYNOTE studies, combining Merck’s Keytruda® in PD-1 checkpoint refractory metastatic melanoma and in late-stage chemo-refractory triple negative breast cancer; has raised over $50M and in October 2019 announced a $30M strategic financing and collaboration with established biopharma partners.
Previously, Mr. O’Connor served as President and CEO of Advaxis Inc., and successfully up-listed the company to NASDAQ and turned around the company, raising more than $300M in funding and licensing deals, transforming it into a patient-focused, leading cancer immunotherapy company. He established major partnerships with companies that included Amgen Inc., Merck & Co. and Bristol-Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda® and Opdivo®. Prior, Mr. O’Connor was the General Counsel and Senior Vice President for ImClone Systems where he led the clinical development, launch and commercialization of ERBITUX®, and positioned ImClone for sale to Eli Lilly in 2008. Mr. O’Connor served as General Counsel at PharmaNet (today, Syneos Health) and was part of the senior leadership team that grew PharmaNet from a start-up contract research organization into a leader in clinical research.
Mr. O’Connor currently serves on the Board of Directors for Seelos Therapeutics. He is a 1995 graduate of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania and previously served as Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned a Lieutenant in the U.S. Marines, attaining the rank of Captain and was deployed to Saudi Arabia for Operation Desert Shield. Mr. O’Connor was a former criminal prosecutor in Somerset County, New Jersey.
Treasurer: Monika A. Vnuk, M.D.
Vice President, R&D Business Development, Pfizer, Inc.
Dr. Monika Vnuk is Vice President of R&D Business Development for Pfizer, Inc. In this role, Dr. Vnuk leads an international team responsible for executing all pre-clinical business development transactions for Pfizer.
Since joining Pfizer in 2008, Dr. Vnuk has been responsible for leading the evaluation, execution and negotiations of many business transactions, including licensing deals, collaborations, joint-ventures and mergers and acquisitions, in support of Pfizer’s Innovative Medicines and Established Medicines businesses across developed and emerging markets.
Before joining Pfizer, Dr. Vnuk was a Vice President at Banc of America Securities. During her time with Banc of America, Dr. Vnuk helped life sciences companies complete initial public offerings, private placements and strategic transactions. Prior to her position at Banc of America, Dr. Vnuk was a Principal at Oxford Bioscience Partners, a venture capital firm focused on early stage biotechnology investments. During her five years with Oxford, she worked with the investment team in forming several biotechnology and medical device start-ups in addition to helping portfolio companies complete private financing transactions. Prior to her role with Oxford Bioscience, Dr. Vnuk was a Fellow at the Health Care Entrepreneurship Program at Boston University.
Dr. Vnuk is a 2000 Inductee to the Alpha Omega Alpha Medical Honor Society. Dr. Vnuk holds a BA in Mathematics and Philosophy from Boston University and an M.D. from Boston University School of Medicine.
Secretary: Michele Korfin, R.Ph., MBA
Chief Operating Officer, TYME Technologies
Ms. Korfin has over 20 years of experience in oncology, focused on product launches, clinical development, oncology marketing strategy, commercial sales, market access and government affairs.
TYME is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. SM-88, is an oral therapy and is the lead investigational agent for the TYME proprietary cancer metabolism-based therapeutics (CMBTsTM) platform.
Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, both solid tumors and hematologic malignancies, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious Grade 3 or higher adverse events. TYME recently announced the start of the pivotal trial for SM-88 in patients with third-line pancreatic cancer.
Prior to joining TYME, Ms. Korfin was Vice President of Market Access at Kite Pharma, where she oversaw the market access strategy, including payer relations, reimbursement and government affairs for Yescarta®, the first approved CAR-T therapy in lymphoma. Ms. Korfin also established the Chain of Identity approach for the Kite CAR-T therapy and led the Kite Konnect team.
Prior to joining Kite, Ms. Korfin spent more than a decade at Celgene in a variety of key strategic and operational roles, including global marketing, head of the U.S. oncology sales force, U.S. market access lead, Lymphoma marketing lead and overseeing the global development programs for REVLIMID® in Lymphoma and CLL.
Ms. Korfin has also held prior positions at Merck & Co. as a manufacturing scientist, Bain & Company as a consultant and Schering-Plough in sales and marketing. Ms. Korfin holds a Master in Business Administration from Harvard Business School and a Bachelor of Science degree in Pharmacy from Rutgers University. Ms. Korfin is a licensed pharmacist in New Jersey. She resides in New Jersey with her husband, Andy, and their two children, Amanda and Jake.
Sol J. Barer, Ph.D.
Former Chairman and CEO, Celgene Corporation
Chairman of the Board, Teva Pharmaceutical Industries
Dr. Barer spent most of his professional career with the Celgene Corporation. He was Chairman from January 2011 until June 2011, Executive Chairman from June 2010 until January 2011 and Chairman and Chief Executive Ofﬁcer from May 2006 until June 2010. Previously he was appointed President in 1993 and Chief Operating Ofﬁcer in 1994 before assuming the CEO position. He also served as Senior Vice President, Science and Technology, and Vice President/General Manager, Chiral Products, from October 1990 to October 1993, and Vice President, Technology, from September 1987 to October 1990. Dr. Barer was the founder of the biotechnology group at the Celanese Research Company which was subsequently spun out to form Celgene.
Dr. Barer currently serves as Chairman of the Board of the public companies Teva Pharmaceutical Industries and Aevi Genomic Medicine and private companies Centrexion and Neximmune, is a Director of 3D Biotherapeutics and is Lead Director of ContraFect. He is the Founding Chair of the HMH Center for Discovery and Innovation. He is a Founder of MIG, an organization dedicated to helping Israeli biotech entrepreneurs and is a Venture Advisor to the Israel Biotechnology Fund as well as an advisor to biopharma companies.
In 2011, Dr. Barer was Chairman of the University of Medicine and Dentistry of New Jersey Governor’s Advisory Committee which resulted in sweeping changes in the structure of New Jersey’s medical schools and public research universities. He previously served as a Commissioner of the NJ Commission on Science and Technology. He was a member of the Board of Trustees of Rutgers University (until 2013). He also served two terms as Chair of the Board of Trustees of BioNJ (2010-2012). Dr. Barer was named to the “Worldview 100” (Scientific American’s 100 most inﬂuential ﬁgures in today’s world of biotechnology) in 2015, named one of “25 Leadership Legends of NJ” (NJBIZ) in 2012, “The 50 Most Powerful People in N.J. Health Care,” in 2012, inducted into the NJBIZ Hall of Fame in 2011 and was named as one of NJ’s top 10 scientists by New Jersey Business in 2008. Dr. Barer has received numerous professional awards.
Vice President, Head of North America Communications & Corporate Social Responsibility, Sanofi
As Head of North America Communications and CSR for Sanofi, Ms. Bechan is responsible for building and overseeing external and internal communication strategies and activities for the North America region, including messaging, media outreach, digital strategy, product communications and executive and internal communications. She also is responsible for the company’s Corporate Social Responsibility initiatives, including corporate giving, volunteerism and social commitments.
Having worked in the communications field for more than 20 years, Ms. Bechan brings to the role extensive experience, both in the U.S. and internationally, to enhance the image and reputation of Sanofi in North America and drive communications excellence in our ever-changing health care environment. In addition to her North America responsibility, Ms. Bechan serves on Sanofi’s Global Communications Leadership Team and the U.S. Country Council. She also serves as the President for the Sanofi Cares Foundation and as the executive sponsor of both the Women Inspiring Sanofi Excellence (WISE) employee resource group and the Sanofi Diversity & Inclusion Council.
Prior to joining Sanofi, Ms. Bechan worked at Takeda Pharmaceuticals International, Inc. for 13 years, where she was most recently Vice President of Corporate Communications responsible for all corporate communications for the company’s four international commercial regions and global manufacturing, including the United States, Emerging Markets, Europe and Canada and North Asia. Ms. Bechan demonstrated her leadership experience in a variety of cultural contexts most notably spending significant time working in Takeda’s Japanese headquarters in Tokyo and living and working in Switzerland. Prior to Takeda, she held positions of increasing responsibility at Edelman Public Relations Worldwide and Andersen Consulting (Accenture).
Ms. Bechan holds a Bachelor of Science degree from the E.W. Scripps School of Journalism at Ohio University. She also completed executive leadership studies at INSEAD and The London Business School.
President, Janssen Oncology and a Member of the Janssen Americas Leadership Team
Mr. Cavanaugh is a results-focused leader with an ability to navigate through complex environments, develop talent and motivate diverse teams. In his current role as President, Janssen Oncology, Mr. Cavanaugh leads the organization in advancing its vision to eliminate cancer. He oversees the strategic direction of an expanding portfolio of transformational therapies in hematology and solid tumor cancers including DARZALEX®, ERLEADA®, IMBRUVICA®, and BALVERSA® while driving a collaborative culture among a team of hundreds working passionately every day to impact patient lives.
Mr. Cavanaugh joined Janssen in September 2017 after a successful career at Celgene where he led the U.S. Hematology/Oncology business. As Corporate Vice-President and General Manager, his leadership was instrumental to exceeding business objectives through innovative approaches, including an enhanced customer engagement initiative that better prepared the organization for future product launches and line extensions.
Over the course of 14 years at Celgene, Mr. Cavanaugh held leadership positions of increasing responsibility in marketing, general management, medical affairs and product development. He was responsible for the initial product launch of REVLIMID and life cycle strategy for REVLIMID and POMALYST®. As Vice President and Global Head of Marketing for Hematology, Mr. Cavanaugh led the design and implementation of disease area strategies for new and in-line products, including portfolio prioritization and resource allocation. His extensive global experience includes two roles in Europe as General Manager of Celgene’s business in Spain and Head of EMEA Marketing in Switzerland. Mr. Cavanaugh joined Celgene from Pharmacia, where he held roles in sales and product management. He began his career as a chemist and pharmacy technician.
Mr. Cavanaugh holds a Bachelor of Arts in Chemistry from North Carolina State University. He lives with his wife and three children in New Jersey.
Jayne C. Gershkowitz
Chief Patient Advocate, Amicus Therapeutics, Inc.
Ms. Gershkowitz joined Amicus Therapeutics in 2006 and serves as Chief Patient Advocate, responsible for developing and executing the global strategies that ensure patients remain at the core of all company operations.
A long-time patient advocacy professional, Ms. Gershkowitz leads the company’s highly regarded Patient and Professional Advocacy department, a function at the heart of Amicus since its earliest days as an R&D organization. She founded the company’s Patient Advisory Boards program, which helps give a voice to the concerns of Patients, families and caregivers and has been actively involved in Amicus’ public policy work to advocate for policies that satisfy unmet needs among those living with rare diseases, and manages Healing Beyond Disease™, an Amicus initiative to further serve the rare disease community in extraordinary ways.
In February of 2019, Ms. Gershkowitz received the second annual “Heart of BioNJ” Award in honor of her selflessness and dedication to patients in the rare disease community. She is also a 2018 PharmaVOICE 100 honoree, recognized for providing inspiration and innovation in the life sciences industry. Ms. Gershkowitz serves on industry, association and non-profit boards and committees, including founding Chair of BioNJ’s Patient Advocacy Committee; member of the Board of Trustees of the Healthcare Institute of NJ (HINJ); member of BIO’s Government Relations and Rare Disease specialty committees; Director of Together Strong; co-founder and board member of Professional Patient Advocates in Life Sciences (PPALS); part of the Corporate Alliance of Global Genes; and former vice-chair of the Board of Directors of the National Organization for Rare Disorders (NORD). Ms. Gershkowitz is the former Executive Director of National Tay-Sachs & Allied Diseases Association.
A native of Medford, Massachusetts, Ms. Gershkowitz graduated from Syracuse University with a dual degree in Public Communications and English Literature and studied marketing management at Radcliffe College. She and her husband, Bruce, reside in Hightstown, New Jersey; they have two adult children.
Christian Kopfli, Esq.
CEO, Chromocell Corporation
Mr. Kopfli co-founded Chromocell in 2002, serving initially as General Counsel before becoming CEO in 2005. Prior to joining Chromocell, he was an Associate at Davis Polk & Wardwell, working in its New York City, Tokyo and Frankfurt offices. At Davis Polk, Mr. Kopfli worked extensively in mergers and acquisitions, capital markets and private equity transactions.
Mr. Kopfli received a doctoral degree in law (magna cum laude) from the University of Zurich in 2000 and earned his LL.M. from Columbia Law School in New York City in 1998. He is admitted to the Bar in New York and Switzerland.
Will Lewis, J.D., MBA
Chairman and CEO, Insmed, Inc.
Mr. Lewis joined Insmed in 2012 as President and CEO and as a member of the Board of Directors. He became Chairman of the Board of Directors in November 2018. Mr. Lewis is the former Co-Founder, President and CFO of Aegerion Pharmaceuticals, Inc., and previously spent more than 10 years working in investment banking in the U.S. and Europe. Prior, Mr. Lewis worked for the U.S. government.
Mr. Lewis holds a BA degree cum laude from Oberlin College as well as an M.B.A. and a J.D. with Honors from Case Western Reserve University.
President, ConSynance Therapeutics
Mr. Maki previously served as CEO of Vicus Therapeutics, as Managing Director of Technology Directors, Inc., as Managing Director of Audax Group and as Principal, Bain Capital, as well as a consultant for Bain & Company.
Mr. Maki holds an AB degree from Harvard University. He has over 25 years of industry experience and has been a founding investor and/or board member of 11 life sciences companies. In addition, four of Mr. Maki’s portfolio companies had successful IPOs and grew to a combined market capitalization exceeding $2.5 billion dollars. Mr. Maki currently serves on the boards of Vicus Therapeutics, an immuno-oncology company and 3DMatrix, a wound healing device company.
Anthony S. Marucci, MBA
Founder, President, CEO and Director, Celldex Therapeutics, Inc.
Mr. Marucci is a Founder of Celldex and serves as the company’s President and CEO and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol-Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci was also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998.
As a member of BioNJ’s Board of Trustees, Mr. Marucci served as its Treasurer through 2010. Mr. Marucci received a BS in Accounting from Kean University, an MBA from Columbia University and an Executive Master of Healthcare Leadership (EMHL) from Brown University.
Jeffrey A. Nau, Ph.D., M.M.S.
President and CEO, Oyster Point Pharma, Inc.
Dr. Nau is currently the President and CEO of Oyster Point Pharma. He has built his career on developing novel, innovative therapies for diseases of the eye, with almost 20 years of experience working with biotechnology, pharmaceutical and medical device companies. Most recently, he was Vice Presicent, Clinical and Medical Affairs, at Ophthotech. Prior to that, Dr. Nau was a Medical Science Director at Genentech working on the development of Lucentis®, a transformative drug for retinal diseases. Dr. Nau has been instrumental in building a number of innovative start-ups, such as Genaera Corporation, Acuity Pharmaceuticals and NeoVista, Inc.
He holds numerous patents and peer-reviewed publications. Dr. Nau has a Ph.D. in Public Health and Epidemiology from Walden University, a M.S. in Medial Science from MCP Hahnemann School of Medicine and a BS in Biology from Stony Brook University.
Greg Oakes, MBA
Corporate Vice President, Amgen
Mr. Oakes joined Amgen in December 2019 after Bristol-Myers Squibb’s acquisition of Celgene. He joined Celgene in July 2017 as Corporate Vice President and General Manager, U.S. Inflammation & Immunology where he was responsible for commercializing Celgene’s I&I portfolio in the United States.
Previously, Mr. Oakes served as Vice President and Head Biopharmaceuticals, North America, Sandoz Inc., a Novartis Division. He led the Sandoz biopharmaceuticals business and was responsible for the development and commercialization of the portfolio, which includes biosimilars, in the U.S. and Canada. Mr. Oakes also served as Senior Vice President and Head of Novartis Pharmaceutical Corporations (NPC) U.S. Managed Markets, Market Access and Primary Care and Established Medicines Business Unit. In addition to having overall responsibility for marketing, sales and the Patient and Specialty Services group, he was able to affect change aligning and strengthening the company’s value proposition across the portfolio to leading customers, including pharmacy benefit managers, insurers, Medicare, Medicaid, chain pharmacies, specialty pharmacies, GPOs, wholesalers and systems of care. Mr. Oakes served as a member of the U.S. General Medicines Executive Committee. Prior to joining Novartis in January 2010, Mr. Oakes worked at Schering-Plough Pharmaceutical Corporation as General Manager, Czech Republic and Slovakia. He also held positions of increasing responsibility within sales and U.S. managed markets, including Vice President, U.S. Managed Markets responsible for the company’s corporate account, specialty market, federal/department of defense, customer marketing, hospital account, generic, retail trade and distribution segments.
Mr. Oakes has a bachelor’s degree in Marketing/Business Administration from Edinboro University, and a Master of Business Administration from Clemson University.
Andrew L. Pecora, M.D., FACP, CPE
CEO, Outcomes Matter Innovations, LLC
A nationally recognized expert in care transformation, Dr. Pecora is at the forefront of the health-systems improvement movement. As CEO of Outcomes Matter Innovations (OMI), he is a national advocate for making medical practices more efficient and profitable, and at the same time, improving patient care. Dr. Pecora, one of Modern Healthcare’s 2019 “50 Most Influential Clinical Executives,” is dedicated to pairing practices with artificial intelligence (AI) and health technologies to increase efficiencies, reduce costs and enable physicians to better do what they do best – heal patients.
Dr. Pecora joined OMI from Hackensack Meridian Health, where he was President, Physician Enterprise and Chief Innovation Officer. A certified hematologist and oncologist – and one of the world’s leading experts in blood and marrow stem cell transplantation, cellular medicine and immunology research – Dr. Pecora played a pivotal role in the recruitment of leading oncologists, initiation of innovative research and clinical trials, expansion of Patient care services and introduction of new, state-of-the-art technologies to shift administrative burdens from healthcare professionals.
While at Hackensack Meridian Health, he created and expanded the John Theurer Cancer Center, named one of the United States top 50 cancer centers – the only New Jersey institute with this designation – and played a key role in the success of multiple Hackensack Meridian strategic partnerships, including those with Memorial Sloan Kettering Cancer Center and Georgetown Lombardi Cancer Center.
Dr. Pecora was instrumental in the John Theurer Cancer Center approval from the National Cancer Institute as a research consortium member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center Consortium, awarded May 2019. This esteemed designation recognizes providers for their scientific leadership, community engagement, and the depth and breadth of their cancer research. The collaboration is one of just 16 NCI-designated cancer consortia.
Along with innovating in clinical settings, Dr. Pecora is a noted leader in building physician alliances. He was instrumental in the creation and development of Regional Cancer Care Associates (RCCA), one of the nation’s largest oncology physician networks. Dr. Pecora is also executive chairman of COTA, a health care software analytics company guiding value-based care delivery for payers and providers. A medical innovator, he co-founded PCT Caladrius, LLC; a company focused on development, manufacturing and delivery of cell-based therapies, later sold to Hitachi.
Dr. Pecora has been awarded the prestigious BioNJ Dr. Sol J. Barer Award for Vision, Innovation and Leadership; the ASCO Cancer Foundation Research Award and Gallo Award for outstanding cancer research; tapped as one of America’s Top Doctors, listed as a “Who’s Who in the World”; and selected as the PM360 Uber ELITE honoree. His award-winning research has been published in numerous peer-review medical journals and funded by organizations including the National Cancer Institute, AHEPA Research Foundation and biopharma giants Amgen and Merck.
Dr. Pecora is a Professor of Medicine and Oncology at Georgetown University and University of Medicine and Dentistry of New Jersey. He is Associate Dean for Technology and Innovation at Hackensack Meridian School of Medicine at Seton Hall University. He received his medical degree from the University of Medicine and Dentistry of New Jersey and completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center.
Stuart W. Peltz, Ph.D.
Chief Executive Officer, PTC Therapeutics, Inc.
Dr. Peltz founded PTC Therapeutics in 1998 and has served as CEO and a member of the Board of Directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for Patients with rare disorders.
Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVOICE’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision, Innovation and Leadership in 2014.
Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.
Navneet Puri, Ph.D.
Founder, Chairman & CEO, Nevakar, Inc.
Dr. Puri is a pharmacist by education with 20 years of healthcare industry experience. He founded Nevakar in 2015 with a vision of creating a fully integrated specialty pharmaceutical company focusing on hospital injectables and ophthalmic products.
Prior to Nevakar, Dr. Puri spent several years in product development and drug delivery of parenteral pharmaceuticals at Baxter Healthcare Corp. and Amgen Inc. He founded InnoPharma, Inc. in 2005, focusing on development of complex generic injectable dosage formulations. When Pfizer acquired InnoPharma in 2014, he stayed on as Vice President of Pfizer’s Worldwide Research & Development until 2015.
Dr. Puri received Future 50 magazine’s Smart CEO award in 2015. He was also awarded the EY Entrepreneur of The Year award from the state of NJ in 2015. Dr. Puri’s past board positions include InnoPharma, Eyenuk and Xeris Pharmaceuticals. His current board positions include Nevakar, Alzeca Biosciences and Rutgers Biomedical and Health Sciences Leadership Council. Dr. Puri earned a MS from the University of Mississippi and a Ph.D. in Pharmaceutics from Rutgers University.
Matthew Roden, Ph.D.
Senior Vice President, Head of Enterprise Strategy, Bristol-Myers Squibb
Dr. Roden is Senior Vice President and Head of Enterprise Strategy at Bristol-Myers Squibb (BMS), overseeing enterprise ambition, key strategic initiatives, annual strategic planning and portfolio management in partnership with business development (BD). Dr. Roden joined BMS in 2016 and prior to his current role, served as Head of Strategic Corporate Development, accountable for acquisitions, structured transactions, strategic equity investing and divestitures, as well as leading BD search and evaluation activities for all therapeutic categories. His strategic and transaction highlights include BMS’ acquisition of Celgene and overseeing the diligence and BD process for over 100 other BD transactions.
Prior to joining BMS, Dr. Roden was Head of Biotechnology Equity Research at UBS Investment Bank. Earlier, he was a Senior Equity Analyst covering biotechnology at J.P. Morgan and Bank of America Merrill Lynch, and was an Associate at Credit Suisse First Boston.
Dr. Roden participated in the New Jersey Governor’s Innovation Evergreen Fund Roundtable; he also served as a Board Observer with IFM Tre, a biotechnology company. He has also served on the Advisory Boards industry leading life sciences venture capital funds; and he and has been an Advisory Committee Board member for various BIO conferences.
Dr. Roden holds a Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine. Earlier, he was awarded a pre-doctoral clinical research fellowship in immuno-oncology at the National Cancer Institute in Bethesda, Maryland. He also holds a M.S. degree from Georgetown University and a BS degree from George Mason University.
Spiro Rombotis, MBA
Cyclacel Pharmaceuticals, Inc., President & Chief Executive Officer
Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has 30 years of experience with biopharmaceutical companies. He was previously Vice President, International Operations and Business Development; Managing Director, Europe; and Representative Director, Japanese joint venture, at The Liposome Company, subsequently acquired by Elan. He held various executive roles at Bristol-Myers Squibb, most recently as Vice President, Pharmaceuticals Central and Eastern Europe. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, subsequently acquired by Johnson & Johnson, and worked in Business Development at Novartis AG.
He holds a BA from Williams College and an MBA and Master’s degree in Hospital Management with honors, from the Kellogg Graduate School of Management, where he serves on the Kellogg Biotech Advisory Board.
Alan L. Rubino
President and CEO, RenovaCare, Inc.
Prior to joining RenovaCare, a public company that is the developer of patented technologies for spraying self-donated stem cells for the regeneration of tissues and organs, Mr. Rubino led a turnaround for Emisphere Technologies, Inc., where he helped to position the company among the leading global oral drug delivery firms. Emisphere’s turnaround was enhanced by a new four molecule collaboration with Novo Nordisk and anchored by the recent FDA approval of Novo Nordisk’s Rybelsus® which incorporated the company’s carrier technology to introduce the first-ever oral GLP-1 therapeutic for the treatment of diabetes. Mr. Rubino also serves on the RenovaCare Corporate Board of Directors.
Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products. New American Therapeutics Inc. achieved major success through the acquisition, marketing and eventual sale of its herpes drug, Denavir® where the team tripled sales in 18 months. Denavir® was then sold to Renaissance Pharmaceuticals, for a multiple of three times sales. Prior to New American Therapeutics Inc., Mr. Rubino served as CEO and President of Akrimax Pharmaceuticals, where he and his team acquired Tirosint® and NitroMist®, two key NDA approved launch products. Rounding out his background, he had also been President and COO of another publicly held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the health care sector with two other public companies, Cardinal Health and PDI Inc.
A major portion of Mr. Rubino’s career includes his 24 years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning.
Mr. Rubino currently serves on the Corporate Boards of Vericel Inc., Genisphere, Inc. and Sanuwave Health, Inc. For over 20 years he served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies.
Mr. Rubino holds a BA in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.
Marco Taglietti, M.D.
President and CEO, SCYNEXIS, Inc.
Dr. Taglietti joined Scynexis’ Board of Directors in 2014 as an independent Director becoming Scynexis’ CEO and President in April 2015. He served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and also as President of the Forest Research Institute until its purchase by Actavis in 2014. During his career at Forest, Stiefel and Schering-Plough, Dr. Taglietti brought to market more than 35 different products in the U.S. and internationally through a variety of regulatory strategies including NDA 505(b)1 and 505(b)2, 510k medical device, ANDA for generics and EMA MAA in many different therapeutic areas, including anti-infectives, oncology, psychiatry, neurology, cardiovascular, respiratory, dermatology, metabolism and internal medicine.
Academic Advisor: Reynold A. Panettieri, Jr., M.D.
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Professor of Medicine, Rutgers University, New Brunswick, New Jersey
Emeritus Professor of Medicine, University of Pennsylvania
Dr. Panettieri is Professor of Medicine, Vice Chancellor for Translational Medicine and Science at Rutgers University, and the Director of the Institute for Translational Medicine and Science. Previously, he was the Robert L. Mayock and David A. Cooper Professor of Medicine in the Pulmonary, Allergy and Critical Care Division of the Department of Medicine, and served as Deputy Director of the Center of Excellence in Environmental Toxicology at the University of Pennsylvania Perelman School of Medicine where he remains Professor Emeritus.
Dr. Panettieri’s basic science interests focus on airway smooth muscle function in asthma and the molecular and cellular mechanisms of airway smooth muscle function and growth. His lab also focuses on cytosolic signaling pathways that mediate gene expression and alter myocyte function. He is principal investigator on several NIH-sponsored grants and industry-sponsored clinical studies, is director of a program project grant examining novel approaches in modulating GPCR function and is the Principal Investigator of the CTSA Hub entitled ‘New Jersey Alliance for Clinical and Translational Science’. He is the author of over 475 peer-reviewed publications.
Dr. Panettieri is the recipient of numerous honors and awards, including the Robert E. Cooke Memorial Lectureship at the American Academy of Allergy, Asthma and Immunology Annual Meeting, the Joseph R. Rodarte Award for Scientific Distinction and the Recognition Award for Scientific Accomplishments from the American Thoracic Society. He is also an active member of national professional and scientific societies, including the American College of Chest Physicians and the American Thoracic Society. In 2013, he was elected Chair of the Respiratory Structure and Function Assembly of the American Thoracic Society.
In addition to his research and clinical interests, Dr. Panettieri served as Chair of the NIH Lung Cellular, Molecular, and Immunobiology Study Section, is a member of the NIH Distinguished Editorial Panel, and is a member of the American Society for Clinical Investigation and Association of American Physicians. He manages the comprehensive clinical care of patients with asthma and is actively involved in clinical investigations focused on the management of asthma and COPD.
Corporate Venture Advisor: Jorge Ramirez, MBA
Principal, H.I.G. BioHealth Partners
Mr. Ramirez focuses on development stage and growth investments in the health care sector at H.I.G. BioHealth Partners. Previously, he was with ProQuest Investments, a health care focused private equity firm. During his eight years with ProQuest, the firm raised and fully invested two funds totaling $625 million. Mr. Ramirez represented ProQuest as an observer or board member in several successful companies, including Eagle Pharmaceuticals, Mevion Medical Systems, Revision Optics and MethylGene (now, Mirati Pharmaceutics). He currently serves on the advisory board of the Commercialization Center for Innovative Technologies, a life sciences incubator funded by the New Jersey Economic Development Authority.
Mr. Ramirez has also held operating roles in health care companies. He was the General Manager of Neurology Products at Cyberkinetics Neurotechnology Systems. He led the regulatory and clinical development teams for an epilepsy monitoring device and had P&L responsibility for Cyberkinetics’ research products. Previously, Mr. Ramirez was a management consultant at Monitor Company.
Mr. Ramirez earned degrees in Neuroscience and Spanish literature from Amherst College, where he graduated magna cum laude. He earned an MBA from Harvard Business School, where he was a Pfizer Scholar and Social Enterprise Fellow.
Legal Advisor: Steven M. Cohen, J.D.
Partner, Morgan, Lewis & Bockius LLP
Chair of the firm’s emerging business and technology practice, Mr. Cohen represents entrepreneurs, private equity investors and venture capital funds. He advises clients in such industries as technology, life sciences, chemicals, consumer products, digital health and fintech. Mr. Cohen counsels mid-Atlantic region investors and emerging growth companies in a variety of business transaction, including equity financing transactions, mergers and acquisitions, divestitures, initial public offerings (IPOs), joint ventures and international strategic partnerships.
With a knack for creating connections between investors and entrepreneurs, Mr. Cohen helps develop and implement growth strategies, working with companies throughout their entire lifecycle.
Widely recognized on the East Coast for his knowledge and skill, Mr. Cohen lectures frequently on emerging technology topics such as planning profitable exit strategies and obtaining angel and venture capital financing for early stage companies.
Mr. Cohen also is also managing partner of the firm’s Princeton office.